Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
Radiation Oncology Journal
; : 166-175, 2019.
Article
em En
| WPRIM
| ID: wpr-761013
Biblioteca responsável:
WPRO
ABSTRACT
PURPOSE:
This study aimed to investigate neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors in patients with locally advanced non-small cell lung cancer (NSCLC) who received concurrent chemoradiotherapy (CCRT). MATERIALS ANDMETHODS:
We retrospectively analyzed 66 patients with locally advanced NSCLC treated with definitive CCRT. Among these patients, 95% received paclitaxel/carboplatin or docetaxel/cisplatin. The median radiation dose was 66 Gy in 33 fractions. The NLR and PLR before/after CCRT were evaluated. The maximally selected log-rank test was used to obtain the cutoff values related to the overall survival (OS).RESULTS:
Patients with high post-CCRT NLR (>3.12) showed worse OS, locoregional progression-free survival (LRPFS), and distant metastasis-free survival (DMFS) than those with low NLR (2-year OS 25.8% vs. 68.2%, p 141) showed worse OS and LRPFS than those with low PLR (2-year OS 37.5% vs. 71.1%, p = 0.004; 2-year LRPFS 16.5% vs. 40.3%, p = 0.040). Patients with high NLR change (>1.61) showed worse OS and LRPFS than those with low NLR change (2-year OS 26.0% vs. 59.0%, p < 0.001; 2-year LRPFS 6.8% vs. 31.8%, p = 0.004). The planning target volume (hazard ration [HR] = 2.05, p = 0.028) and NLR change (HR = 3.17, p = 0.025) were the significant factors for OS in the multivariate analysis.CONCLUSION:
NLR change after CCRT was associated with poor prognosis of survival in patients with locally advanced NSCLC. An elevated NLR after CCRT might be an indicator of an increased treatment failure risk.Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Prognóstico
/
Análise Multivariada
/
Estudos Retrospectivos
/
Falha de Tratamento
/
Carcinoma Pulmonar de Células não Pequenas
/
Intervalo Livre de Doença
/
Quimiorradioterapia
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Radiation Oncology Journal
Ano de publicação:
2019
Tipo de documento:
Article